V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220013860 | 220008291 | null | 74 | Curative (C) | 2014-10-17 | 2014-10-17 | Rituximab | N | N | 220031504 | RITUXIMAB |
| 220013861 | 220008291 | 1.68 | 0 | null | 2017-03-03 | 2017-07-03 | AML 18 TRIAL | null | N | 220031504 | AML18 TRIAL |
| 220013862 | 220019839 | 0 | 63 | null | 2013-06-05 | 2013-06-05 | AML18 PILOT TRIAL | N | N | 220031508 | PILOT TRIAL |
| 220013863 | 220008293 | null | null | Curative (C) | 2018-05-25 | 2018-10-24 | Dasatinib | N | N | 220031509 | DASATINIB |
| 220013864 | 220014510 | 1.82 | null | Palliative (P) | 2014-03-01 | 2015-04-01 | Dasatinib | 99 | null | 220031510 | DASATINIB |
| 220013865 | 220014510 | 1.6 | null | Disease modification (D) | 2018-04-07 | 2018-05-16 | Rituximab | N | N | 220031510 | RITUXIMAB |
| 220013866 | 220014510 | 1.8 | 95.1 | Curative (C) | 2013-08-05 | 2013-08-09 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220031510 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013867 | 220008295 | 1.66 | null | Neo-adjuvant (N) | 2013-03-09 | 2013-12-11 | Dasatinib | 99 | N | 220031522 | DASATINIB |
| 220013868 | 220008296 | 1.96 | null | Adjuvant (A) | 2019-02-13 | 2019-02-13 | Dasatinib | N | null | 220031524 | DASATINIB |
| 220013869 | 220008297 | null | 75 | Palliative (P) | 2017-12-12 | 2017-12-12 | AML 18 TRIAL | 1 | N | 220031525 | AML18 TRIAL |
| 220013871 | 220014511 | 1.78 | 64.9 | Adjuvant (A) | 2016-04-30 | 2016-08-14 | AML18 PILOT TRIAL | N | null | 220031527 | PILOT TRIAL |
| 220013872 | 220008299 | 1.58 | 69.9 | Palliative (P) | 2013-07-01 | 2013-07-01 | Dasatinib | 2 | N | 220031530 | DASATINIB |
| 220013873 | 220008300 | 1.64 | 0 | Curative (C) | 2018-03-12 | 2018-03-12 | Dasatinib | N | N | 220031530 | DASATINIB |
| 220013875 | 220008302 | 1.69 | 70 | Curative (C) | 2014-05-16 | 2014-05-16 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 220031548 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013876 | 220008303 | 1.75 | 127 | Disease modification (D) | 2015-10-07 | 2015-10-25 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220031551 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013877 | 220008306 | 1.67 | null | Palliative (P) | 2012-12-01 | 2013-12-02 | Dasatinib | N | null | 220031554 | DASATINIB |
| 220013878 | 220008307 | null | 0 | Palliative (P) | 2014-08-20 | 2014-08-20 | Dasatinib | 02 | null | 220031559 | DASATINIB |
| 220013879 | 220014513 | 0 | null | Palliative (P) | 2014-01-21 | 2014-01-21 | Dasatinib | N | N | 220031562 | DASATINIB |
| 220013880 | 220014513 | 1.75 | null | Curative (C) | 2013-07-01 | 2013-09-26 | AML 18 TRIAL | N | N | 220031562 | AML18 TRIAL |
| 220013881 | 220014513 | 1.62 | 100 | Disease modification (D) | 2013-03-06 | 2013-03-07 | AML 18 TRIAL | 01 | N | 220031562 | AML18 TRIAL |
| 220013882 | 220008308 | null | 63 | null | 2014-11-10 | 2015-03-11 | AML18 PILOT TRIAL | N | null | 220031581 | PILOT TRIAL |
| 220013883 | 220014514 | 1.61 | 106 | Curative (C) | 2013-10-17 | 2013-10-17 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220031587 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013884 | 220008311 | 1.66 | 73 | Curative (C) | 2016-04-07 | 2016-04-07 | AML 18 TRIAL | 1 | N | 220031587 | AML18 TRIAL |
| 220013885 | 220008313 | null | 63.1 | Curative (C) | 2016-05-15 | 2016-05-22 | Alemtuz+Fludara+Melphalan RIC MUD | null | N | 220031589 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013886 | 220008314 | null | 81 | null | 2016-02-11 | 2016-08-18 | Rituximab | 2 | N | 220031596 | RITUXIMAB |
| 220013889 | 220008316 | null | 61.2 | null | 2017-10-27 | 2017-11-02 | FLAG | N | N | 220031604 | FLAG |
| 220013890 | 220008317 | null | 90.8 | Disease modification (D) | null | 2014-07-23 | ATG + Busulfan + Fludarabine | null | null | 220031606 | ATG + BUSULFAN + FLUDARABINE |
| 220013891 | 220017932 | 0 | 90 | Palliative (P) | 2012-12-31 | 2013-03-01 | Triple Intrathecal | 2 | Y | 220031607 | TRIPLE INTRATHECAL |
| 220013892 | 220008324 | 0 | 71.5 | Disease modification (D) | 2018-10-25 | 2018-11-06 | RUXOLITINIB | 2 | N | 220031607 | RUXOLITINIB |
| 220013893 | 220008325 | 1.77 | 77.6 | Palliative (P) | null | 2018-10-06 | BOSUTINIB | N | N | 220031609 | BOSUTINIB |
| 220013894 | 220020943 | 1.64 | 80 | Disease modification (D) | 2017-09-30 | 2017-09-30 | Methotrexate intrathecal | N | N | 220031618 | METHOTREXATE INTRATHECAL |
| 220013895 | 220020943 | 1.62 | 75 | Curative (C) | 2016-09-17 | 2016-09-17 | CYCLOPHOSPHAMIDE | N | N | 220031618 | CYCLOPHOSPHAMIDE |
| 220013896 | 220020943 | 1.6 | null | Disease modification (D) | 2014-02-24 | 2014-02-25 | Methotrexate intrathecal | 02 | N | 220031618 | METHOTREXATE INTRATHECAL |
| 220013897 | 220014524 | 1.7 | null | Curative (C) | 2015-08-25 | 2015-08-25 | Methotrexate intrathecal | 2 | N | 220031622 | METHOTREXATE INTRATHECAL |
| 220013898 | 220008329 | 1.51 | null | Curative (C) | 2013-12-05 | 2013-12-05 | Triple Intrathecal | N | N | 220031623 | TRIPLE INTRATHECAL |
| 220013899 | 220008331 | null | 50.5 | Curative (C) | 2017-12-24 | 2017-12-25 | BOSUTINIB | null | N | 220031625 | BOSUTINIB |
| 220013900 | 220008333 | 1.66 | 75 | Curative (C) | 2016-06-05 | 2016-06-05 | Methotrexate intrathecal | 2 | N | 220031628 | METHOTREXATE INTRATHECAL |
| 220013901 | 220014526 | 1.63 | 0 | Curative (C) | 2013-08-02 | 2013-09-22 | Cyclophosphamide TBI Allograft | 02 | Y | 220031628 | CYCLOPHOSPHAMIDE |
| 220013902 | 220008334 | 1.74 | 0 | Curative (C) | 2017-04-06 | 2017-04-06 | ATG + Busulfan + Fludarabine | N | N | 220031645 | ATG + BUSULFAN + FLUDARABINE |
| 220013906 | 220008338 | 1.68 | null | Disease modification (D) | 2014-01-06 | 2014-01-07 | Triple / Double Intrathecal Therapy | 02 | N | 220031663 | TRIPLE INTRATHECAL |
| 220013907 | 220008339 | 1.6 | 55.5 | Not known (9) | 2015-07-14 | 2015-11-30 | AML16 DA 3+8 | N | Y | 220031663 | AML16 TRIAL |
| 220013908 | 220008340 | 1.75 | 93 | Disease modification (D) | 2014-06-08 | 2014-06-08 | BOSUTINIB | N | N | 220031680 | BOSUTINIB |
| 220013909 | 220014530 | 1.78 | 118.5 | Curative (C) | null | 2016-10-15 | Cyclophosphamide oral | N | null | 220031680 | CYCLOPHOSPHAMIDE |
| 220013910 | 220008342 | 1.7 | null | Palliative (P) | 2013-11-21 | 2013-11-24 | FLAG | 2 | N | 220031681 | FLAG |
| 220013911 | 220008343 | 1.51 | null | Curative (C) | null | 2013-03-06 | FLAG | N | N | 220031687 | FLAG |
| 220013912 | 220008348 | 1.65 | 65.4 | Disease modification (D) | 2014-07-05 | 2014-07-05 | Methotrexate intrathecal | N | N | 220031688 | METHOTREXATE INTRATHECAL |
| 220013913 | 220014533 | 1.77 | 61.5 | Curative (C) | 2015-05-20 | 2015-05-20 | BOSUTINIB | 2 | N | 220031689 | BOSUTINIB |
| 220013914 | 220017938 | 1.65 | 82 | Curative (C) | 2015-08-26 | 2015-08-26 | FLAG | 2 | N | 220031691 | FLAG |
| 220013915 | 220017938 | null | 25.8 | Palliative (P) | 2015-10-26 | 2015-10-26 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220031691 | IDARUBICIN + TRETINOIN |
| 220013916 | 220008350 | 1.75 | 69 | Curative (C) | 2017-03-12 | 2017-03-12 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031700 | ADE |